Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ImmunoPrecise Antibodies Ltd. (V:IPA)

Business Focus: Biopharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for IPA within the last 6 months
See all filings within the past 6 months

Company News

Oct 13, 2021 18:26 ET
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA), a leader in full-service therapeutic antibody discovery and development, today announced that it has entered into an At-The-Market Distribution Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sole sales agent (the “Agent”). Under the ATM Agreement, the Company will be entitled, at its discretion and from time-to-time during the term of the ATM Agreement, to sell, through the Agent common shares of the Company (the “Common Shares”) having an aggregate gross sales price of up to US$50 mil
Read full article
Oct 07, 2021 08:38 ET
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) and the Pierre Fabre pharmaceutical group announced today that IPA’s subsidiary, Talem Therapeutics LLC (“Talem”), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talem’s portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biot
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 15, 202153,5792,339
Sep 30, 202151,240-764
Sep 15, 202152,004-1,167
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

ImmunoPrecise Antibodies Ltd. is a technology platform company that supports pharmaceutical and biotechnology companies. The Company discover, develop, engineer and manufacture therapeutic antibodies against all classes of disease targets. The Company transforms the conventional multi-vendor antibody discovery model by providing a suite of services tailored to improve antibody genetic diversity and epitope coverage, to discover antibodies against rare epitopes. The Company offers support to its partners with customized, computational project design, antigen preparation, an on-site vivarium, immunization services, discovery platforms, functional antibody testing, lead candidate selection, antibody optimization, antibody engineering and manufacturing. The Company's services include B cell sorting, phage display, abthena bispecifics, LucinaTech Humanization, affinity maturation, immunization, hybridoma, sequencing and cell line development.

See business summary



Search (past week) for $IPA.CA IPA.V